Arcutis has launched a virtual health platform connecting over 45 million US patients with eczema, seborrheic dermatitis and plaque psoriasis to independent, board-certified dermatologists for ZORYVE evaluation. Digital intake and a pharmacy hub provide insurance support and home delivery of ZORYVE prescriptions.
Arcutis launches a virtual health platform targeting over 45 million US patients with eczema, seborrheic dermatitis and plaque psoriasis to expand access to its ZORYVE portfolio. The digital service connects individuals to independent, board-certified dermatologists after a brief online clinical intake.
Participating dermatologists evaluate, diagnose and determine appropriate treatment based solely on clinical judgment, with no influence from Arcutis. This streamlined process aims to shorten wait times and overcome geographic barriers to specialist dermatology care.
When prescribed, ZORYVE orders are managed through a national pharmacy hub that handles insurance support and home delivery, while also offering direct shipment to patients’ preferred pharmacies. This centralized coordination ensures a seamless start to therapy.
The platform complements traditional in-office dermatology by offering flexible digital appointments for patients facing scheduling or geographic challenges. This initiative underscores Arcutis’s commitment to broadening timely access to its immuno-dermatology treatments and reducing barriers to specialist care.
